Blame drug 'middlemen' for Ozempic and Wegovy prices, Novo Nordisk CEO tells Congress
CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to drug middlemen and the ‘complex’ U.S. health care system today during a committee hearing in Congress.
Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.
Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...
WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo ...
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
O faturamento da farmacêutica dinamarquesa Novo Nordisk com o Ozempic e o Wegovy é tanto que as vendas acumuladas logo ...
Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback